Merck & Co., Inc. (MRK) Tops Q2 EPS by 5c

July 29, 2014 6:56 AM EDT

(Updated - July 29, 2014 6:59 AM EDT)

Merck & Co., Inc. (NYSE: MRK) reported Q2 EPS of $0.85, $0.05 better than the analyst estimate of $0.80. Revenue for the quarter came in at $10.93 billion versus the consensus estimate of $10.6 billion.

“We delivered a strong first half of the year, making progress in transforming our operating model, fueling innovation and managing costs, while focusing on our best opportunities,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I’m excited as we are preparing for a series of important and promising product launches later this year that we believe will make a meaningful difference to patients, healthcare providers and payers, while creating value for society and shareholders.”

The following table reflects sales of the company's top pharmaceutical products, as well as total sales of Animal Health and Consumer Care products.

Second Quarter Second Quarter Change Change
$ in millions 2014 2013 Ex-exchange
Total Sales $10,934 $11,010 -1% -1%
Pharmaceutical 9,087 9,310 -2% -2%
JANUVIA/JANUMET 1,577 1,547 2% 2%
ZETIA/VYTORIN 1,134 1,067 6% 5%
REMICADE 607 527 15% 9%
ISENTRESS 453 412 10% 10%
GARDASIL 409 383 7% 9%
PROQUAD, M-M-R II and VARIVAX 326 339 -4% -3%
SINGULAIR 284 281 1% 3%
NASONEX 258 325 -21% -20%
Animal Health 872 851 2% 3%
Consumer Care 583 490 19% 20%
Other Revenues 392 359 9% 6%

*** Outlook:

The company sees FY14 adjusted EPS of $3.43 - $3.53, versus consensus expectations of $3.48.

In addition, the company continues to expect full-year 2014 non-GAAP marketing and administrative as well as R&D expenses to be below 2013 levels. The company continues to anticipate its full-year 2014 non-GAAP tax rate to be in the range of 24 to 26 percent; the rate does not include a 2014 benefit of an R&D tax credit.

For earnings history and earnings-related data on Merck & Co., Inc. (MRK) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance, Management Comments

Related Entities

Earnings